ASLN News and Press, ASLAN Pharmaceuticals Limited From 03/12/24

SAN MATEO, Calif. and SINGAPORE, March 12, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals Ltd. (Nasdaq: ASLN), a clinical-stage, immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced today announced that it has entered in...

2024-03-12 08:28:49 ET More on Pre-market losers & stocks. Renalytix approached by potential buyer, stock rallies 28% Renalytix surges after Medicare draft decision on lead product Seeking Alpha’s Quant Rating on ASLAN Pharmaceuticals Historical ea...

TREK-DX, the first randomized, double-blind, placebo-controlled study to be conducted in a dupilumab -experienced atopic dermatitis (AD) patient population, has started enrolling patients in the US under an updated protocol; new European sites are on track to open in the first half of...

New translational data from a head-to-head study of eblasakimab and dupilumab in a human tissue model of COPD shows eblasakimab performed better than dupilumab in improving airway function and enhancing bronchodilation at the same concentrations ...

A look at the top 10 most actives in the United States Marathon Digital Holdings Inc. (MARA) rose 2.4% to $31.03 on volume of 179,649,718 shares Vivani Medical Inc. (VANI) rose 270.3% to $3.74 on volume of 148,811,385 shares Nikola Corporation (NKLA) rose 1.7% to $0.7684 on volume of 121,...

New Composition of Matter Patent for farudodstat would strengthen intellectual property protection and provide commercial exclusivity for farudodstat until at least 2043 SAN MATEO, Calif. and SINGAPORE, Feb. 29, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals Ltd....

A look at the top 10 most actives in the United States Marathon Digital Holdings Inc. (MARA) rose 1.8% to $30.87 on volume of 148,760,969 shares Vivani Medical Inc. (VANI) rose 291.9% to $3.9579 on volume of 141,227,838 shares Nikola Corporation (NKLA) rose 2.6% to $0.7758 on volume of 10...

Following the successful TREK-AD Phase 2b study of eblasakimab in moderate-to-severe atopic dermatitis, process is underway to identify potential partners. Recruitment in TREK-DX, studying eblasakimab in dupilumab -experienced patients, using updated cr...

SAN MATEO, Calif. and SINGAPORE, Nov. 20, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage, immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, CEO, will participate in a fir...

Head-to-head study between eblasakimab and dupilumab in skin biopsies from atopic dermatitis (AD) patients confirm eblasakimab ’s differentiated effects of targeting IL-13R vs IL-4R Using an established COPD model of human lung slices, new data demonstrate eblasakimab &...